Novartis exercised an option to acquire global rights to Sironax’ brain delivery platform, paying $125 million at closing. The technology is intended to help deliver a range of therapeutic modalities across the blood-brain barrier, supporting Novartis’ pipeline in central nervous system indications. Sironax will retain development, manufacturing and commercialization rights for selected assets, using the proceeds to fund multiple clinical-stage programs and additional early candidates tied to its aging-focused biology. The deal stems from an option and asset purchase agreement announced in July 2025. The acquisition highlights continued interest in CNS delivery platforms as companies look to improve exposure for modalities that face biological barriers. It also adds another monetization and platform-licensing model to Novartis’ R&D restructuring efforts after setbacks in neuroscience. If Novartis can translate the delivery improvement into clearer clinical exposure-and-efficacy relationships, the platform could support multiple follow-on CNS programs beyond the initial asset set.